Related Experiment Video
Updated: Apr 8, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin in breast cancer - an evolving mystery
Laura Camacho1, Atreyi Dasgupta1, Sao Jiralerspong1,2
1Lester and Sue Smith Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. jiralers@bcm.edu.
Abstract:
Metformin, a diabetes drug with well-established side effect and safety profiles, has been widely studied for its anti-tumor activities in a number of cancers, including breast cancer. But its mechanism of action in the clinical arena remains elusive. In a window of opportunity trial of metformin in non-diabetic breast cancer patients, Dowling and colleagues examined both the direct actions of the drug on cancer cells (as mediated by AMP kinase), as well as its indirect actions (as mediated by circulating insulin). The data suggest that short-term administration of metformin in this setting has anti-tumor effects significantly involving the indirect, insulin-dependent pathway. The role of the direct pathway remains to be determined. This study represents an important step forward in establishing one of several possible mechanisms for metformin, information that will be useful in determining candidate biomarkers to evaluate in large clinical trials of metformin, such as the ongoing NCIC CTG MA.32 trial of adjuvant metformin. The potential significance of these data for metformin in the treatment of breast cancer is discussed here.
Insights
Metformin shows anti-tumor effects in breast cancer by reducing circulating insulin, not directly impacting cancer cells. This finding aids in identifying biomarkers for future metformin trials.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Metformin, a common diabetes medication, exhibits potential anti-cancer properties.
- Its precise mechanism of action in cancer treatment, particularly breast cancer, remains unclear.
- Understanding metformin's effects is crucial for optimizing its clinical use in oncology.
Purpose of the Study:
- To investigate the clinical mechanism of action of metformin in non-diabetic breast cancer patients.
- To differentiate between direct (AMP kinase-mediated) and indirect (insulin-mediated) effects of metformin.
- To identify potential biomarkers for metformin efficacy in breast cancer.
Main Methods:
- A window of opportunity clinical trial involving non-diabetic breast cancer patients.
- Assessment of metformin's direct effects on cancer cells via AMP kinase.
- Evaluation of metformin's indirect effects through modulation of circulating insulin levels.
Main Results:
- Short-term metformin administration demonstrated significant anti-tumor effects in breast cancer.
- The primary mechanism involved the indirect pathway, significantly reducing circulating insulin.
- The direct anti-cancer effects mediated by AMP kinase were not conclusively determined in this study.
Conclusions:
- Metformin's anti-tumor activity in breast cancer appears to be predominantly mediated by its indirect, insulin-lowering effects.
- Further research is needed to elucidate the role of direct pathways.
- These findings support the ongoing investigation of metformin in large-scale clinical trials for breast cancer treatment and prevention.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution